Kinase targeting in Luminal A breast cancer: PIK3R1.

Fuente: Zenodo
Saved in:
Bibliographic Details
Main Author: Mamoor, Shahan
Format: Recurso digital
Published: Zenodo 2025
Online Access:
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1866901782386442240
author Mamoor, Shahan
author_facet Mamoor, Shahan
contents <p dir="ltr">Breast cancer can be positive for expression of a hormone receptor (ESR/PGR/AR) or a growth factor receptor (ERBB2).  Disease recurrence following disease remission (relapse), resistance to endocrine therapy or otherwise inadequate long-term control of disease are challenges that limit effectiveness of existing drugs that treat luminal A and luminal B receptor disease.  Here we utilized whole transcriptome technologies (5, 6) to measure total transcription in the primary tumors of humans with luminal A and luminal B breast cancer.  We describe one member of a group of kinases up-regulated and differentially expressed in human luminal A breast cancer, PIK3R1, as a catalytically available enzyme and candidate therapeutic target for the adjunctive medical treatment of luminal A breast cancer.    </p>
format Recurso digital
id zenodo_https___doi_org_10_5281_zenodo_16912649
institution Zenodo
language
publishDate 2025
publisher Zenodo
record_format zenodo
spellingShingle Kinase targeting in Luminal A breast cancer: PIK3R1.
Mamoor, Shahan
<p dir="ltr">Breast cancer can be positive for expression of a hormone receptor (ESR/PGR/AR) or a growth factor receptor (ERBB2).  Disease recurrence following disease remission (relapse), resistance to endocrine therapy or otherwise inadequate long-term control of disease are challenges that limit effectiveness of existing drugs that treat luminal A and luminal B receptor disease.  Here we utilized whole transcriptome technologies (5, 6) to measure total transcription in the primary tumors of humans with luminal A and luminal B breast cancer.  We describe one member of a group of kinases up-regulated and differentially expressed in human luminal A breast cancer, PIK3R1, as a catalytically available enzyme and candidate therapeutic target for the adjunctive medical treatment of luminal A breast cancer.    </p>
title Kinase targeting in Luminal A breast cancer: PIK3R1.
url https://doi.org/10.5281/zenodo.16912649